EPHA1
Ephrin type-A receptor 1
Also known as: EPH, EPHA1_HUMAN, EPHT, EPHT1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P21709
- Gene
- EPHA1
- Ensembl
- ENSG00000146904
- Chromosome
- 7
- Canonical length
- 976 aa
- Protein class
- Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene is expressed in some human cancer cell lines and has been implicated in carcinogenesis. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
976 residues, UniProt reviewed canonical sequence.
>P21709|EPHA1
1 MERRWPLGLG LVLLLCAPLP PGARAKEVTL MDTSKAQGEL GWLLDPPKDG WSEQQQILNG
61 TPLYMYQDCP MQGRRDTDHW LRSNWIYRGE EASRVHVELQ FTVRDCKSFP GGAGPLGCKE
121 TFNLLYMESD QDVGIQLRRP LFQKVTTVAA DQSFTIRDLV SGSVKLNVER CSLGRLTRRG
181 LYLAFHNPGA CVALVSVRVF YQRCPETLNG LAQFPDTLPG PAGLVEVAGT CLPHARASPR
241 PSGAPRMHCS PDGEWLVPVG RCHCEPGYEE GGSGEACVAC PSGSYRMDMD TPHCLTCPQQ
301 STAESEGATI CTCESGHYRA PGEGPQVACT GPPSAPRNLS FSASGTQLSL RWEPPADTGG
361 RQDVRYSVRC SQCQGTAQDG GPCQPCGVGV HFSPGARGLT TPAVHVNGLE PYANYTFNVE
421 AQNGVSGLGS SGHASTSVSI SMGHAESLSG LSLRLVKKEP RQLELTWAGS RPRSPGANLT
481 YELHVLNQDE ERYQMVLEPR VLLTELQPDT TYIVRVRMLT PLGPGPFSPD HEFRTSPPVS
541 RGLTGGEIVA VIFGLLLGAA LLLGILVFRS RRAQRQRQQR QRDRATDVDR EDKLWLKPYV
601 DLQAYEDPAQ GALDFTRELD PAWLMVDTVI GEGEFGEVYR GTLRLPSQDC KTVAIKTLKD
661 TSPGGQWWNF LREATIMGQF SHPHILHLEG VVTKRKPIMI ITEFMENGAL DAFLREREDQ
721 LVPGQLVAML QGIASGMNYL SNHNYVHRDL AARNILVNQN LCCKVSDFGL TRLLDDFDGT
781 YETQGGKIPI RWTAPEAIAH RIFTTASDVW SFGIVMWEVL SFGDKPYGEM SNQEVMKSIE
841 DGYRLPPPVD CPAPLYELMK NCWAYDRARR PHFQKLQAHL EQLLANPHSL RTIANFDPRM
901 TLRLPSLSGS DGIPYRTVSE WLESIRMKRY ILHFHSAGLD TMECVLELTA EDLTQMGITL
961 PGHQKRILCS IQGFKDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against EPHA1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 194 nTPM
Expression across tissuesHPA
Tissue
- parathyroid gland: 194 nTPM
- esophagus: 56 nTPM
- vagina: 25 nTPM
- skin: 19 nTPM
- cervix: 17 nTPM
- liver: 16 nTPM
Single-cell type
- papillary tip epithelial cells: 9.3 nCPM
- loop of henle epithelial cells: 5 nCPM
- renal collecting duct principal cells: 5 nCPM
- early spermatids: 4.7 nCPM
- proximal tubule cells: 3.6 nCPM
- renal connecting tubule cells: 3.5 nCPM
Immune cell
- naive CD4 T-cell: 3.8 nTPM
- naive CD8 T-cell: 2.9 nTPM
- memory CD4 T-cell: 1.9 nTPM
- total PBMC: 1 nTPM
- memory CD8 T-cell: 0.5 nTPM
- plasmacytoid DC: 0.4 nTPM
Brain region
- choroid plexus: 2.6 nTPM
- cerebellum: 0.9 nTPM
- cerebral cortex: 0.3 nTPM
- white matter: 0.3 nTPM
- amygdala: 0.2 nTPM
- basal ganglia: 0.2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.05
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.22
- DepMap mean gene effect
- 0
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- angiogenesis
- cell surface receptor protein tyrosine kinase signaling pathway
- negative regulation of cell migration
- positive regulation of angiogenesis
- positive regulation of cell migration
- positive regulation of cell-matrix adhesion
- positive regulation of stress fiber assembly
- substrate adhesion-dependent cell spreading
Molecular functions
- ATP binding
- ephrin receptor activity
- fibronectin binding
- protein kinase binding
- transmembrane receptor protein tyrosine kinase activity
- transmembrane-ephrin receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Protein kinase domain
- Ephrin, ligand binding domain
- Serine-threonine/tyrosine-protein kinase, catalytic domain
- Tyrosine-protein kinase, receptor class V, conserved site
- Sterile alpha motif domain
- Fibronectin type III
- Tyrosine-protein kinase, active site
- Galactose-binding-like domain superfamily
- Growth factor receptor cysteine-rich domain superfamily
- Protein kinase-like domain superfamily
- Tyrosine-protein kinase ephrin type A/B receptor-like
- Sterile alpha motif/pointed domain superfamily
- Immunoglobulin-like fold
- Ephrin receptor type-A /type-B
- Protein kinase, ATP binding site
- Tyrosine-protein kinase, catalytic domain
- Ephrin, transmembrane domain
- Fibronectin type III superfamily
- Ephrin receptor tyrosine kinases
- Fibronectin type III domain
- SAM domain (Sterile alpha motif)
- Ephrin receptor ligand binding domain
- Tyrosine-protein kinase ephrin type A/B receptor-like
- Protein tyrosine and serine/threonine kinase
- Ephrin type-A receptor 2 transmembrane domain
- Ephrin cysteine rich domain
- Ephrin type-A receptor 1, ligand binding domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of EPHA1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads EPHA1 as an antibody target. Whether an autoantibody or antibody against EPHA1 could matter depends on whether native EPHA1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
EPHA1 is annotated at the cell surface, where native EPHA1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label EPHA1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...